TORL BioTherapeutics Raises $158M in Series B Financing
Summary
TORL BioTherapeutics, a Los Angeles, CA-based biopharmaceutical company focused on developing new biologics for cancer treatment, closed a $158m Series B financing. Amit Sinha, Head of Life Sciences Investing within Goldman Sachs Asset Management, and Lynn Seely, M.D., President and CEO of Lyell Immunopharma, will join TORL Board of Managers as part of Series B financing. Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well as leadership from a distinguished set of industry veterans, including Executive Chairman Mark Alles, former Chairman and CEO of Celgene Corporation, TORL BioTherapeutics is a clinical-stage biopharmaceutical company with the objective of developing novel, antibody-based therapeutics to transform the lives of cancer patients. Its lead candidate, TORL-1-23, is a CLDN6-directed ADC developed for patients across multiple cancer types. Additionally, TORL is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications with a high unmet medical need.
Funding
Review available funding amount, funding date, investors, and linked company information related to TORL BioTherapeutics Raises $158M in Series B Financing in the interactive ISVWorld profile.